Form 4: Fortress Biotech Acquires Shares in Checkpoint Therapeutics as Equity Fee

Fortress Biotech acquired 193,905 shares of Checkpoint Therapeutics common stock on March 20, 2024, as an equity fee related to a financing.

Summary

• On March 20, 2024, Fortress Biotech, Inc. acquired 193,905 shares of Checkpoint Therapeutics, Inc. common stock.
• The acquisition was an equity fee granted by Checkpoint Therapeutics to Fortress Biotech, representing 2.5% of the gross amount of a financing.
• The price per share was $0.00, indicating it was a grant rather than a purchase.
• Following the transaction, Fortress Biotech directly owns 2,096,278 shares of Checkpoint Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by Fortress Biotech as part of a financing agreement is a routine event. The increased stake could be seen as a positive sign of confidence, but it's primarily a contractual obligation.

Positives

• Fortress Biotech's increased stake in Checkpoint Therapeutics could signal confidence in the latter's prospects.
• The equity fee arrangement aligns Fortress Biotech's interests with Checkpoint Therapeutics' success in securing financing.

Industry Context

Equity fee arrangements are common in the biotech industry, particularly for companies like Checkpoint Therapeutics that rely on external financing to fund research and development. Fortress Biotech's role as a significant shareholder and potential financing partner is typical of investment firms specializing in the biotech sector.

Comparison to Industry Standards

• Comparing this transaction to similar equity fee arrangements in the biotech industry would require analyzing the terms of other financing deals involving comparable companies.
• For example, companies like Sorrento Therapeutics or Mustang Bio, which also rely on external funding, may have similar arrangements with their investors.
• The 2.5% equity fee should be compared to industry benchmarks for similar financing deals to assess whether it is a standard rate.

Stakeholder Impact

• Shareholders of Checkpoint Therapeutics may see this as a positive sign of continued financial support from Fortress Biotech.
• The transaction has a limited impact on employees, customers, suppliers, and creditors.

Key Dates